Lanean...
Golimumab for the treatment of ulcerative colitis
Introduction: Tumor necrosis factor antagonists have revolutionized the therapeutic management of inflammatory bowel disease. Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis. More recently, a third tumor necrosis factor antagonis...
Gorde:
| Argitaratua izan da: | Expert Opin Biol Ther |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5490638/ https://ncbi.nlm.nih.gov/pubmed/28472597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2017.1327576 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|